['hodgkin disease']
['nivolumab', 'doxorubicin', 'vinblastine', 'dacarbazine']

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Must have received prior high-dose conditioning chemotherapy followed by autologous
             stem cell transplant (ASCT) as a part of salvage therapy for cHL (cohort A, B & C -
             enrollment closed)

          -  Participants may be Brentuximab vedotin- naïve, or may have had prior Brentuximab
             vedotin treatment (cohort A, B & C - enrollment closed)

          -  Newly diagnosed and previously untreated classical Hodgkin Lymphoma (cohort D)

        Exclusion Criteria:

          -  Known central nervous system lymphoma

          -  Participants with nodular lymphocyte-predominant Hodgkin Lymphoma

          -  Prior allogeneic stem cell transplantation (SCT)

          -  Chest radiation ≤ 24 weeks prior to first dose

          -  Carmustine ≥ 600 mg/m² received as part of the pre-transplant conditioning regimen
      